Faculty profile

Scott Harrison

ResearcherSchool of Population and Public HealthUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Scott Harrison

Researcher

School of Population and Public Health

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
16 publications in the last five years, latest in 2025.
Principal investigator on 1 research grant (1 CIHR), most recently in 2017.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Harm Reduction Opioid Dependency Patient-Centered Care Rehabilitation Treatment

Latest papers

Building Capacity for Injectable Diacetylmorphine and Hydromorphone for the Treatment of Opioid Use Disorder: Identifying Typical Doses.
Journal of psychoactive drugs · 2025
Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT).
Substance abuse treatment, prevention, and policy · 2024
Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best-worst scaling task.
Addiction (Abingdon, England) · 2024

All 38 publications

Latest funding

Program of Outcomes Research on Treatment with Injectables for Addiction: Accessibility Needs and Tangible Actions
CIHR · 2023 · Co-investigator
$100,000
Program of Outcomes Research on Treatment with Injectables for Addiction
CIHR · 2018 · Co-investigator
$1,101,600
Patient-Centered Care for Addictions Treatment: A Scoping Review
CIHR · 2017 · Principal investigator
$58,070

All 8 grants and awards

38 publications.

Building Capacity for Injectable Diacetylmorphine and Hydromorphone for the Treatment of Opioid Use Disorder: Identifying Typical Doses.

Magel T, Arreola LAG, Guh D, MacDonald S, Harrison S, Schechter M, Oviedo-Joekes E

Journal of psychoactive drugs2025

DOI: 10.1080/02791072.2024.2338734 PMID: 38590251

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT).

Beaumont S, Magel T, MacDonald S, Harrison S, Schechter M, Oviedo-Joekes E

Substance abuse treatment, prevention, and policy2024

DOI: 10.1186/s13011-023-00585-4 PMID: 38172882

Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best-worst scaling task.

Metcalfe RK, Dobischok S, Bansback N, MacDonald S, Byres D, Lajeunesse J, Harrison S, Koch B, Topping B, Brock T, Foreman J, Schechter M, Oviedo-Joekes E

Addiction (Abingdon, England)2024

DOI: 10.1111/add.16620 PMID: 39054406

The mobilization of nurse-client therapeutic relationships in injectable opioid agonist treatment: Autonomy, advocacy and action.

Blawatt S, Harrison S, Byres D, Foreman J, Amara S, Burdge W, MacDonald S, Schechter MT, Oviedo-Joekes E

Journal of substance use and addiction treatment2023

DOI: 10.1016/j.josat.2023.209154 PMID: 37652211

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review.

Adams A, Blawatt S, Magel T, MacDonald S, Lajeunesse J, Harrison S, Byres D, Schechter MT, Oviedo-Joekes E

Substance abuse treatment, prevention, and policy2023

DOI: 10.1186/s13011-023-00564-9 PMID: 37777766

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review.

Adams A, Blawatt S, MacDonald S, Finnick R, Lajeunesse J, Harrison S, Byres D, Schechter MT, Oviedo-Joekes E

The International journal on drug policy2023

DOI: 10.1016/j.drugpo.2023.104058 PMID: 37182352

Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study.

Oviedo-Joekes E, Dobischok S, Carvajal J, MacDonald S, McDermid C, Klakowicz P, Harrison S, LaJeunesse J, Chow N, Brown M, Gill S, Schechter M

BMC health services research2023

DOI: 10.1186/s12913-023-09558-6 PMID: 37237256

"As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises.

Jaffe K, Blawatt S, Lehal E, Lock K, Easterbrook A, MacDonald S, Harrison S, Lajeunesse J, Byres D, Schechter M, Oviedo-Joekes E

Harm reduction journal2023

DOI: 10.1186/s12954-023-00779-w PMID: 37060027

Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).

Dobischok S, Metcalfe R, Matzinger E, Palis H, Marchand K, Harrison S, MacDonald S, Byres D, Schechter M, Bansback N, Oviedo-Joekes E

The International journal on drug policy2023

DOI: 10.1016/j.drugpo.2022.103948 PMID: 36586152

Changes in daily dose in open-label compared to double-blind: The role of clients' expectations in injectable opioid agonist treatment.

Blawatt S, Arreola LAG, Magel T, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E

Addictive behaviors reports2023

DOI: 10.1016/j.abrep.2023.100490 PMID: 37124402

Something wrong or missing on this profile? Suggest a correction

Scott Harrison

Research

Latest papers

Latest funding

Building Capacity for Injectable Diacetylmorphine and Hydromorphone for the Treatment of Opioid Use Disorder: Identifying Typical Doses.

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT).

Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best-worst scaling task.

The mobilization of nurse-client therapeutic relationships in injectable opioid agonist treatment: Autonomy, advocacy and action.

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review.

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review.

Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study.

"As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises.

Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).

Changes in daily dose in open-label compared to double-blind: The role of clients' expectations in injectable opioid agonist treatment.

Frequent collaborators

Eugenia Oviedo-Joekes

Kirsten Marchand

Heather Palis

Kurt Lock

Martin Schechter

David Byres

Seonaid Nolan

Evan Wood

Lianping Ti

Thomas Kerr

Patricia Spittal

Samantha Young

Mohammad Karamouzian

Patrick McDougall

Mark Lysyshyn

Marilou Gagnon

Adrian Guta

Nadia Fairbairn

Jane Buxton

Soo Ying Chan Carusone

Eric Grafstein

Mel Krajden

Julio Montaner

Mark Hull

Soo Chan Carusone

Carol Strike

Keith Ahamad